Setting a new standard for transplant patients
The cobas® BKV test provides reliable, standardised, high-quality results for clinical decision-making and for the improved management of transplant patients at risk of infection. Healthcare professionals use this test to assess if transplant patients are at risk of developing disease caused by BKV, which can contribute to organ rejection. The test is for use on the automated cobas® 6800/8800 Systems in countries accepting the CE mark.
Features and benefits of the cobas® BKV test
- Standardisation – Results traceable to the WHO International Standard and reporting in IU/mL for improved harmonisation in testing results across hospitals and institutions
- State-of-the-art design – Best-in-class performance with dual target assay designs to provide reliable and reproducible results for reassurance in clinical decision making
- Efficiency, flexibility and simplicity – Ability to perform critical transplant testing (CMV, EBV, BKV) from a single EDTA plasma sample on the cobas® 6800/8800 Systems with an industry-leading menu, for proven performance and allowing for absolute automation
- Enabling BKV Urine testing the right way – Urine sample is stabilised in cobas® PCR media allows to maintain the integrity of results, enable faster preparation, without the need of refrigeration, making storage and transportation more convenient
BKV could cause transplant-transmitted infections in immunocompromised transplant patients and is linked to post-transplant complications, such as nephropathy in kidney transplants and hemorrhagic cystitis in hematopoietic stem cell transplants.2 Early intervention with best-in-class monitoring tools provides actionable results which enable informed treatment decisions.